Back

Evaluating standard risk prediction tools for predicting cardiotoxicity in patients receiving fluoropyrimidine chemotherapy

19 June 2026 (11:12 - 11:21)
Organised by: Logo
Congress Presentation Part of: Stratifying the risk of cardiotoxicity Stratification, Prevention and Monitoring Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Aderonke Abiodun

Barts Health Trust, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Coronary artery calcium quantification on routine contrast-enhanced CT-scans in patients with cancer receiving immune checkpoint inhibitors: a prospective cohort study
Miss A. Strijdhorst (Amsterdam, NL)
Abstract Slides
Presentation thumbnail
Cardiotoxicity following BRAF and MEK inhibitor therapy: a meta-analysis of prevalence
Doctor D. Koeckerling (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Baseline and early changes in cardiac biomarkers as predictors of global longitudinal strain deterioration during breast cancer therapy: a PRADAII substudy
Doctor V. Vinje (Nordbyhagen, NO)
Abstract Slides
Presentation thumbnail
Sex influence on cancer incidence after a cardiovascular event: a population study
Doctor H. Morillas Climent (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
Stratifying the risk of cardiotoxicity
Video

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 11:12 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources